Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

LONDON--(BUSINESS WIRE) March 13, 2024 -- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the“Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials